Richard Yeh
Director/Board Member at MEDLIVE TECHNOLOGY CO., LTD.
Profile
Richard Yeh is currently a Director at I-MAB Biopharma Co., Ltd.
He is also an Independent Non-Executive Director at ADICON Holdings Ltd.
and Medlive Technology Co., Ltd.
Mr. Yeh's former jobs include being the CFO, Director & Head-Strategic Operations at Abbisko Therapeutics Co., Ltd., Director, Chief Operating & Financial Officer at I-Mab, and CFO, Executive Director & Head-Operations at Abbisko Cayman Ltd.
He has also worked as a Research Associate at Amgen, Inc. and as a Research Analyst at Citigroup Global Markets, Inc. Mr. Yeh has an MBA from Cornell University, a graduate degree from the University of Toronto, and an undergraduate degree from the University of Manitoba.
Richard Yeh active positions
| Companies | Position | Start |
|---|---|---|
| ADICON HOLDINGS LIMITED | Director/Board Member | 2021-06-23 |
| MEDLIVE TECHNOLOGY CO., LTD. | Director/Board Member | 2021-07-13 |
I-MAB Biopharma Co., Ltd.
 I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Director/Board Member | - |
Former positions of Richard Yeh
| Companies | Position | End |
|---|---|---|
| I-MAB | Director of Finance/CFO | 2024-02-04 |
| ABBISKO CAYMAN LIMITED | Director of Finance/CFO | 2022-04-27 |
Abbisko Therapeutics Co., Ltd.
 Abbisko Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology Abbisko Therapeutics Co., Ltd. engages in the research and development of biomedicine and biotechnology. Its business includes technology transfer, technical advisory, and technical services. The company was founded on April 12, 2016 and is headquartered in Shanghai, China. | Director of Finance/CFO | 2022-03-31 |
| CSTONE PHARMACEUTICALS | Director of Finance/CFO | 2020-03-31 |
Goldman Sachs (Asia) LLC
 Goldman Sachs (Asia) LLC Investment Banks/BrokersFinance Goldman Sachs (Asia) LLC (GS-Asia) is the Hong Kong-based brokerage subsidiary of Goldman Sachs Holdings (Hong Kong) Ltd., ultimately owned by The Goldman Sachs Group, Inc. (NYSE: GS), a multinational investment bank and financial services company headquartered in New York City. Founded in 1984, GS-Asia provides market insight, risk management and execution services to institutional clients which includes asset managers, hedge funds, banks and brokerages, pensions, endowments and foundations, corporations, and governments. | Analyst-Equity | 2018-07-06 |
Training of Richard Yeh
| Cornell University | Masters Business Admin |
| University of Toronto | Graduate Degree |
| University of Manitoba | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 6 |
|---|---|
| AMGEN INC. | Health Technology |
| CSTONE PHARMACEUTICALS | Health Technology |
| ADICON HOLDINGS LIMITED | Health Services |
| I-MAB | Health Technology |
| MEDLIVE TECHNOLOGY CO., LTD. | Commercial Services |
| ABBISKO CAYMAN LIMITED | Health Technology |
| Private companies | 9 |
|---|---|
Citigroup Global Markets, Inc. (Broker)
 Citigroup Global Markets, Inc. (Broker) Investment Banks/BrokersFinance Citigroup Global Markets, Inc. (Broker) (CGMI-Broker) is the broker/dealer division of Citigroup Global Markets, Inc., an investment bank headquartered in New York City with additional offices across the US. The firm was founded in 2004 and is a subsidiary of Citigroup Financial Products, Inc., ultimately held by Citigroup, Inc. (NYSE: C). CGMI-Broker covers all market capitalizations of the major global indices and provides macro and quantitative analysis of global markets and sector trends. Their core focus of the group is to help investing clients make informed decisions by providing value-added, independent, insightful analysis. | Finance |
Canaccord Adams, Inc.
 Canaccord Adams, Inc. Investment Banks/BrokersFinance Canaccord Adams, Inc. is an independent financial services firm and broker/dealer headquartered in Boston with additional offices in New York City, San Francisco, Evanston, Illinois and Houston, Texas. The firm provides research to help clients make informed investment decisions. Their analysts seek to identify opportunities and expose risk with a focus on emerging and small- to mid-cap growth companies. Canaccord Adams focuses on seven sectors, clarifying current events and anticipating market trends in high-quality daily, weekly and monthly research products. The seven sectors they focus on are: metals and mining, energy, technology, life sciences, real estate and gaming, consumer and industrial growth. Canaccord Adams is a subsidiary of Vancouver-based Canaccord Financial, Inc. They are a member of the NASD and the SIPC. | Finance |
GenoSpectra, Inc.
 GenoSpectra, Inc. BiotechnologyHealth Technology Genospectra, Inc. was a life science company developing technologies and products for Parallel Quantitative Biology (PQB). Genospectra's PQB initiative was focused on creating novel cell-based assays and tools that enable multiplex measurements of molecular events, such as intracellular pathway analysis, in a quantitative and scalable manner. Genospectra's first product line, the QuantiGene Reagent System was launched in 2003, and was powered by the FDA approved and proprietary branched DNA technology for gene expression analysis in cell-based assays. Genospectra was headquartered in Fremont, CA. | Health Technology |
Wyeth Pharmaceuticals LLC
 Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Health Technology |
Needham & Co. LLC
 Needham & Co. LLC Investment Banks/BrokersFinance Needham & Co. LLC (Needham) is a registered investment advisor and broker/dealer headquartered in New York City. The firm was founded in 1985 and is a wholly-owned indirect subsidiary of The Needham Group, Inc. Needham provides corporate and institutional clients with high quality research, corporate access, capital markets and trading execution services in both the public and private markets, with an emphasis on growth companies. | Finance |
Citigroup Global Markets Asia Ltd.
 Citigroup Global Markets Asia Ltd. Investment Banks/BrokersFinance Citigroup Global Markets Asia Ltd. (CGMA) is a securities brokerage firm headquartered Hong Kong. They are a subsidiary of Citigroup Global Markets Hong Kong Holdings Ltd., ultimately owned by Citigroup, Inc. (NYSE: C) in the US. Formerly known as Citi Smith Barney, the firm was reorganized in 2008 when Citigroup combined their brokerage and private banking businesses. CGMA offers stock trading services to various institutional investors. | Finance |
Goldman Sachs (Asia) LLC
Goldman Sachs (Asia) LLC Investment Banks/BrokersFinance Goldman Sachs (Asia) LLC (GS-Asia) is the Hong Kong-based brokerage subsidiary of Goldman Sachs Holdings (Hong Kong) Ltd., ultimately owned by The Goldman Sachs Group, Inc. (NYSE: GS), a multinational investment bank and financial services company headquartered in New York City. Founded in 1984, GS-Asia provides market insight, risk management and execution services to institutional clients which includes asset managers, hedge funds, banks and brokerages, pensions, endowments and foundations, corporations, and governments. | Finance |
Abbisko Therapeutics Co., Ltd.
Abbisko Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology Abbisko Therapeutics Co., Ltd. engages in the research and development of biomedicine and biotechnology. Its business includes technology transfer, technical advisory, and technical services. The company was founded on April 12, 2016 and is headquartered in Shanghai, China. | Health Technology |
I-MAB Biopharma Co., Ltd.
I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Health Technology |
- Stock Market
- Insiders
- Richard Yeh
